C-peptide vs Bremelanotide
Head-to-head comparison of C-peptide (Connecting peptide (C-peptide)) and Bremelanotide (Bremelanotide (PT-141), cyclic melanocortin receptor agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | C-peptide | Bremelanotide |
|---|---|---|
| Category | Pain Management | Sexual Health |
| Full Name | Connecting peptide (C-peptide) | Bremelanotide (PT-141), cyclic melanocortin receptor agonist |
| Molecular Weight | 3020.3 Da | 1025.2 Da |
| Half-Life | ~20-30 min | about 2.7 h |
| Amino Acids | 31 | 7 |
| Typical Dose | no approved analgesic dose|research-only | 1.75 mg |
| Route | IV|subQ | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 46 | 200 |
| Research Status | Pre-clinical | Clinical |
C-peptide Benefits
- ✓diabetic neuropathy research
- ✓nerve function support
- ✓possible analgesic effect
Bremelanotide Benefits
- ✓increases sexual desire
- ✓supports arousal
- ✓may improve erectile response
- ✓on-demand use
C-peptide Dosing
0.5-1.0 mg/day in research|route varies by protocol
Bremelanotide Dosing
1.75 mg subcutaneous PRN|administer about 45 minutes before activity|max 1 dose per 24 hours
C-peptide Side Effects
- ⚠injection-site reactions
- ⚠unknown long-term safety
Bremelanotide Side Effects
- ⚠nausea
- ⚠flushing
- ⚠headache
- ⚠transient blood pressure increase
Research Overview
C-peptide
C-peptide is not an approved analgesic, but multiple studies have examined its effects on peripheral nerve blood flow and neuropathy outcomes. The strongest relevance is in diabetic neuropathic pain rather than migraine.
Bremelanotide
Human studies and approval data support meaningful effects on sexual desire in women, with a central mechanism involving melanocortin signaling. It is one of the most clinically relevant peptides in this category and is commonly used as the reference compound for PT-141-type research.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.